Phaseline

Targets › COL4A1

COL4A1 (Collagen alpha-1(IV) chain [Cleaved into: Arresten]): drug programs, companies and trials

1 program from 1 company in 6 trials: 5 Phase 4, 1 Phase 3; Genitourinary, Other; next expected readout Dec 2027.

Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen..; FUNCTION: Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. (UniProt, P02462)

Open in Phaseline: the race on COL4A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Endo USA Inc., a Keenova Therapeutics CompanyCollagenase Clostridium Histolyticum (KN3835)
Collagen hydrolytic enzyme
COL1A2, COL1A1, COL2A1, COL3A1, COL4A1Phase 3Flexible Hammertoe; Peyronie Disease; Peyronie's Disease; Dupuytren Disease of Finger …Dec 2027

Conditions

Peyronie Disease (2) Flexible Hammertoe (1) Peyronie's Disease (1) Dupuytren Disease of Finger (1) Dupuytren Contracture (1)

Modalities

protein or peptide (1)

Companies

Endo USA Inc., a Keenova Therapeutics Company (1)

Related targets

COL1A2 (1) COL1A1 (1) COL2A1 (1) COL3A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.